George Karavetsos’ last day is Jan. 20, which coincidentally is the start of the Trump Administration. Office of Criminal Investigations has been subject of recent Congressional scrutiny.
After a two-year stint as head of FDA’s Office of Criminal Investigations, George Karavetsos is leaving the agency to join an unspecified private law firm. His last day is Jan. 20, Inauguration Day.
The timing of his departure is apparently a coincidence. Karavetsos is not a political appointee and thus is not required...
Recent studies show that spaceflight can significantly weaken astronauts’ immune systems, making them more susceptible to infections and health complications during and after missions. Understanding these changes is crucial for ensuring the safety of future long-duration space travelers.
Recent ODAC meetings suggest the FDA will expand focus beyond applications with pending approval decisions to refining trial designs and drug labels for competitors.
The US FDA Commissioner pushed for a rebalancing of the US’s pharmaceutical supply chains while also stressing that there is a role for US-China commerce that would be risky to compromise.
Recent ODAC meetings suggest the FDA will expand focus beyond applications with pending approval decisions to refining trial designs and drug labels for competitors.
The US FDA Commissioner pushed for a rebalancing of the US’s pharmaceutical supply chains while also stressing that there is a role for US-China commerce that would be risky to compromise.
